EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HER2-Targeted Therapy—From Pathophysiology to Clinical Manifestation: A Narrative Review

Svetoslava Elefterova Slavcheva, Atanas Angelov

Journal of Cardiovascular Development and Disease · 06.12.2023 · 10 (12) · 489

DOI: 10.3390/jcdd10120489 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 06.12.2023. Verfasst von Svetoslava Elefterova Slavcheva und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Diseases, EC Cardiology, Faculty of Medicine, Medical University "Prof. Dr. Paraskev Stoyanov", 9000 Varna, Bulgaria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab is the primary treatment for all stages of HER2-overexpressing breast cancer in patients. Though discovered over 20 years ago, trastuzumab-induced cardiotoxicity (TIC) remains a research topic in cardio-oncology. This review explores the pathophysiological basis of TIC and its clinical manifestations. Their understanding is paramount for early detection and cardioprotective treatment. Trastuzumab renders cardiomyocytes susceptible by inhibiting the cardioprotective NRG-1/HER2/HER4 signaling pathway. The drug acts on HER2-receptor-expressing cardiomyocytes, endothelium, and cardiac progenitor cells (see the Graphical Abstract). The activation of immune cells, fibroblasts, inflammation, and neurohormonal systems all contribute to the evolution of TIC. A substantial amount of research demonstrates that trastuzumab induces overt and subclinical left ventricular (LV) systolic failure. Data suggest the development of right ventricular damage, LV diastolic dysfunction, and heart failure with preserved ejection fraction. Further research is needed to define a chronological sequence of cardiac impairments to guide the proper timing of cardioprotection implementation.

Schlagwörter

Stichwörter der Autor:innen

cardiotoxicityclinical manifestationpathophysiologytrastuzumab

Autor:innen und Institutionen

  • First Department of Internal Diseases, EC Cardiology, Faculty of Medicine, Medical University "Prof. Dr. Paraskev Stoyanov", 9000 Varna, Bulgaria.
  • First Cardiology Clinic with Intensive Cardiology Activity, University Multiprofessional Hospital of Active Treatment "St. Marina", 9000 Varna, Bulgaria.

Zitieren

APA

Slavcheva, S. E., & Angelov, A. (2023). HER2-Targeted Therapy—From Pathophysiology to Clinical Manifestation: A Narrative Review. Journal of Cardiovascular Development and Disease, 10(12), 489. https://doi.org/10.3390/jcdd10120489

Vancouver

Slavcheva SE, Angelov A. HER2-Targeted Therapy—From Pathophysiology to Clinical Manifestation: A Narrative Review. Journal of Cardiovascular Development and Disease. 2023;10(12):489. doi:10.3390/jcdd10120489

BibTeX
@article{Slavcheva2023,
  author = {Slavcheva, Svetoslava Elefterova and Angelov, Atanas},
  title = {HER2-Targeted Therapy—From Pathophysiology to Clinical Manifestation: A Narrative Review},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2023},
  volume = {10},
  number = {12},
  pages = {489},
  doi = {10.3390/jcdd10120489}
}
Kostenlos starten →